Mirabegron
- Generic Name
- Mirabegron
- Brand Names
- Myrbetriq, Betmiga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24N4O2S
- CAS Number
- 223673-61-8
- Unique Ingredient Identifier
- MVR3JL3B2V
- Background
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...
- Indication
Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 568
- Registration Number
- NCT02656173
- Locations
- 🇯🇵
Site JP81043, Fukuoka, Japan
🇯🇵Site JP81048, Fukuoka, Japan
🇯🇵Site JP81003, Hokkaido, Japan
Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 221
- Registration Number
- NCT02622555
- Locations
- 🇸🇪
Daniel Altman, Stockholm, Sweden
Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Jean-Luc Balligand
- Target Recruit Count
- 296
- Registration Number
- NCT02599480
- Locations
- 🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Belgium
🇫🇷Nantes university hospital (CHU Nantes), Nantes, France
🇩🇪University Medical Center Göttingen (UMG-GOE), Göttingen, Germany
Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 316
- Registration Number
- NCT02570035
- Locations
- 🇯🇵
Site JP81007, Chiba, Japan
🇯🇵Site JP81001, Hokkaido, Japan
🇯🇵Site JP81025, Hyogo, Japan
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 113
- Registration Number
- NCT02540707
- Locations
- 🇨🇳
Outpatient clinics, Department of Obs/Gyn, National Taiwan University Hospital, Taipei, Taiwan
Mirabegron in Parkinson Disease and Impaired Cognition
- Conditions
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- HealthPartners Institute
- Target Recruit Count
- 7
- Registration Number
- NCT02536976
- Locations
- 🇺🇸
Struthers Parkinson's Center, Golden Valley, Minnesota, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
- Conditions
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 9
- Registration Number
- NCT02526979
- Locations
- 🇵🇱
Site PL48001, Warsaw, Poland
🇩🇰Site DK45002, Aalborg, Denmark
🇩🇰Site DK45001, Aarhus, Denmark
Mirabegron and Urinary Urgency Incontinence
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 84
- Registration Number
- NCT02495389
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- CHU de Quebec-Universite Laval
- Target Recruit Count
- 35
- Registration Number
- NCT02476175
Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- CHU de Quebec-Universite Laval
- Target Recruit Count
- 58
- Registration Number
- NCT02468830
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.